KalVista Pharmaceuticals Inc. (4XC1)
XDUS 
Summary
4XC1 Chart
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive
KalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind. Looking ahead, Ekterly's potential pediatric expansion into ages 2 to 11 could add meaningful upside.
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KalVista Pharmaceuticals Inc. (4XC1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has KalVista Pharmaceuticals Inc. ever had a stock split?
KalVista Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Benjamin L. Palleiko CEO | XDUS Exchange | US4834971032 ISIN |
| US Country | 150 Employees | 22 Nov 2016 Last Dividend | 22 Nov 2016 Last Split | 9 Apr 2015 IPO Date |
Overview
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors to address diseases with significant unmet medical needs in the United States. With its headquarters located in Cambridge, Massachusetts, the company is dedicated to pushing the boundaries of medical research to bring forward innovative therapies that can improve the lives of patients facing challenging conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME).
Products and Services
- Sebetralstat: This is a novel small molecule plasma kallikrein inhibitor that is entering the Phase 3 KONFIDENT trial. It represents a potential oral, on-demand therapy for HAE attacks. The development of Sebetralstat underscores KalVista's commitment to providing alternative treatment solutions for patients struggling with hereditary angioedema, offering hope for more control over their condition with an orally administered medication.
- Factor XIIa Oral Inhibitor Program: Currently in the preclinical stage, this oral inhibitor targets the Factor XIIa enzyme, which plays a critical role in the pathophysiology of HAE. By focusing on this novel target, KalVista aims to pioneer a different approach to managing HAE, paving the way for potentially more effective and patient-friendly treatments in the future.
